Results 71 to 80 of about 10,664 (186)

Severe Immediate and Delayed Hypersensitivity Reactions to Biologics in a Toddler With Systemic Juvenile Idiopathic Arthritis

Journal of Investigative Medicine High Impact Case Reports, 2022
Many pediatric rheumatic diseases can be safely managed with biologic therapy. Severe allergic reactions to these medications are uncommon. We report the case of a 2-year-old male with systemic-onset juvenile idiopathic arthritis and secondary macrophage
D. Sofia Villacis-Nunez MD, Kassahun Bilcha MD, Mary Spraker MD, Kelly Rouster-Stevens MD, Anthony Cooley MD   +4 more
doaj   +1 more source

Double-blind randomized proof-of-concept trial of canakinumab in patients with COVID-19 associated cardiac injury and heightened inflammation

, 2021
AIMS: In coronavirus disease 2019 (COVID-19), myocardial injury is associated with systemic inflammation and higher mortality. Our aim was to perform a proof of concept trial with canakinumab, a monoclonal antibody to interleukin-1β, in patients with ...
Culver, Daniel A, Rajendram, Prabalini, Menon, Venu, Nissen, Steven E, Brennan, Danielle M, Lincoff, A Michael, Wang, Tom Kai Ming, Wolski, Katherine E, Sheng, Calvin C, Hassan, Ossama K Abou, Wolinsky, David A, Sahoo, Debasis, Prada, Robier Aguillon, Cremer, Paul C, Dugar, Siddharth, Duggal, Abhijit, Hernandez-Montfort, Jamie   +16 more
core   +1 more source

Cardiovascular disease incidence and cancer risk in two large European prospective cohorts

International Journal of Cancer, EarlyView.
What's New? Cardiovascular disease (CVD) and cancer share risk factors and biological mechanisms, raising questions about potential associations between the two, particularly regarding CVD duration and cancer onset. Whether CVD influences subsequent cancer risk, however, remains inconclusive.
Emma Fontvieille, Vivian Viallon, Laia Peruchet‐Noray, Quan Gan, N. Charlotte Onland‐Moret, Yvonne Koop, Anne Tjønneland, Nicola Patricia Bondonno, Verena Katzke, Rudolf Kaaks, Matthias B. Schulze, Catarina Schiborn, Calogero Saieva, Vittorio Simeon, Claudia Agnoli, Rosario Tumino, Fulvio Ricceri, Leila Luján‐Barroso, Maria‐José Sánchez, Conchi Moreno‐Iribas, Konstantinos K. Tsilidis, Marc J. Gunter, Adam Butterworth, Elio Riboli, Heinz Freisling, Pietro Ferrari   +25 more
wiley   +1 more source

TRIM31–LOX‐1 Axis: A Novel Therapeutic Frontier in Atherosclerosis

iNew Medicine, EarlyView.
ABSTRACT Atherosclerosis, driven by a vicious cycle of lipid accumulation and chronic inflammation, underlies most cardiovascular diseases. Macrophages exacerbate this process by internalizing oxidized low‐density lipoprotein (oxLDL), forming foam cells, and releasing inflammatory mediators. A recent study published in Circulation identified the TRIM31–
Qian Zhang, Cheng Xue Qin
wiley   +1 more source

Long-term safety and effectiveness of canakinumab in patients with monogenic autoinflammatory diseases: results from the interim analysis of the RELIANCE registry

RMD Open
Objective Interim analysis of the RELIANCE registry, an on-going, non-interventional, open-label, multicentre, prospective study evaluating the long-term safety, dosing regimens and effectiveness of canakinumab in patients with cryopyrin-associated ...
Tilmann Kallinich, Juergen Rech, Ivan Foeldvari, Norbert Blank, Frank Weller-Heinemann, Gerd Horneff, Ioana Andreica, Joerg Henes, Jasmin B Kuemmerle-Deschner, Florian Meier, Frank Dressler, Michael Borte, Markus Hufnagel, Birgit Kortus-Götze, Prasad T Oommen, Tobias Krickau, Aleš Janda, Catharina Schuetz, Michael Fiene, Julia Weber-Arden   +19 more
doaj   +1 more source

Systematic literature review of efficacy/effectiveness and safety of current therapies for the treatment of cryopyrin-associated periodic syndrome, hyperimmunoglobulin D syndrome and tumour necrosis factor receptor-associated periodic syndrome

RMD Open, 2020
Objectives Several therapies are used for the treatment of rareautoinflammatory conditions like cryopyrin-associated periodic fever syndromes (CAPS), hyperimmunoglobulin Dsyndrome (HIDS)/mevalonate kinase deficiency (MKD) and tumour necrosis factor ...
Peter Hur, Syed Raza, Jasmin Beate Kuemmerle-Deschner, Raju Gautam, Aneesh Thomas George, Kathleen Graham Lomax   +5 more
doaj   +1 more source

Therapy with canakinumab for gout

, 2019
A significant part of patients with gout has contraindications to taking nonsteroidal anti-inflammatory drugs, colchicine and glucocorticoids. Such therapy is often ineffective, particularly in patients with the severe tophaceous gout what hampers ...
E. L. Nasonov, M. S. Eliseev
core   +1 more source

Precision environmental medicine: Integrated multi‐exposure transcriptomics for shared molecular networks in COPD pathogenesis in response to environmental exposure

Precision Medical Sciences, EarlyView.
This integrated systems biology study of 2847 exposure‐related genes identifies a conserved 647‐gene core and CYP1B1 hub across cigarette smoke, ozone, and PM2.5. Three key pathways converge, enabling computational repurposing of 15 drug candidates (e.g., NRF2 activators) for environmentally induced COPD.
Fakher Rahim, Gürler Akpinar, Kenesh Dzhusupov   +2 more
wiley   +1 more source

Canakinumab treatment real world evidence in 3 monogenic periodic fever syndromes in 2009–2022: an interim analysis using the French JIR cohort database

Arthritis Research & Therapy
Background Our study aimed to provide real-world evidence on the treatment patterns, effectiveness and safety of canakinumab in France in Familial Mediterranean Fever (FMF), Mevalonate Kinase Deficiency (MKD), and Tumor necrosis factor Receptor ...
Isabelle Koné-Paut, Sophie Georgin-Lavialle, Alexandre Belot, Magali Jover, Mathilde Pouriel, Laure Lacoin, Pascal Pillet, Véronique Hentgen   +7 more
doaj   +1 more source

Adjunctive canakinumab reduces peripheral inflammation markers and improves positive symptoms in people with schizophrenia and inflammation: A randomized control trial

BACKGROUND Clinical trials of anti-inflammatories in schizophrenia do not show clear and replicable benefits, possibly because patients were not recruited based on elevated inflammation status.
Weickert, T.W., Adith Mohan, Isabella Jacomb, Brown, D., Shannon Weickert, Cynthia, Cherrie Galletly, Rhoshel Lenroot, David Brown, Pellen, D., Jochen Kindler, O'Donnell, Maryanne, Lloyd, A.R., Maryanne O'Donnell, Lappin, J., Mohan, Adith, Clive Stanton, Stanton, C., Dennis Liu, Weinberg, Danielle, Lenroot, R., Wakefield, D., Brown, David, Shannon Weickert, C., Pellen, Daniel, Kindler, J., O'Donnell, M., Daniel Pellen, Cynthia Shannon Weickert, Thomas W. Weickert, Lloyd, Andrew R, Julia Lappin, Lenroot, Rhoshel, Galletly, C., William S. Brooks, Stanton, Clive, Weinberg, D., Jacomb, I., Liu, D., Kindler, Jochen, Weickert, Thomas W, Lappin, Julia, Liu, Dennis, Brooks, W.S., Jacomb, Isabella, Brooks, William S, Wakefield, Denis, Mohan, A., Danielle Weinberg, Andrew R. Lloyd, Denis Wakefield, Galletly, Cherrie   +50 more
core   +1 more source